Director, US Medical Affairs, PDAC

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

The Opportunity:

The Director, US Medical Affairs - PDAC will support the development and execution of the US Medical Affairs strategy and tactical plan for pancreatic ductal adenocarcinoma (PDAC). The role will serve as a US medical and scientific partner for cross-functional teams and help translate the evolving PDAC treatment landscape, external expert perspectives, and field insights into focused medical priorities and activities.

The Director will contribute to launch readiness and post-approval medical activities, including scientific engagement, evidence generation, medical communications, internal education, and patient-focused initiatives. This individual will work closely with US Field Medical, Clinical Development and Operations, Medical Information, Medical Communications, HEOR/RWE, Biomarker and Companion Diagnostics, Commercial, Market Access, Regulatory, Safety, Legal, and Compliance.

The ideal candidate is scientifically rigorous, collaborative, proactive, and comfortable operating in a fast-paced environment. The individual should be able to synthesize complex evidence, develop clear scientific narratives, and execute medical tactics that address meaningful needs in PDAC care.

- Contributes to the development and execution of the US Medical Affairs strategy and annual medical plan for PDAC, including launch readiness, launch execution, and lifecycle planning.

- Translates US-specific evidence gaps, treatment patterns, stakeholder needs, and field insights into clear medical objectives and executable tactics.

- Leads or supports scientific engagement with US external experts through advisory boards, investigator interactions, congress activities, and peer-to-peer scientific exchange.

- Partners with US Field Medical to develop scientific priorities, insight-generation plans, training, and resources that support high-quality scientific exchange.

- Synthesizes insights from external experts, field teams, advisory boards, and other medical activities and communicate implications to internal stakeholders.

- Serves as the PDAC medical content expert on US cross-functional teams and provide scientifically balanced medical input into strategic discussions and decisions.

- Partners with HEOR/RWE, Clinical Development, and Biomarker/Companion Diagnostics teams on evidence-generation priorities addressing US clinical practice, patient identification, biomarker testing, treatment sequencing, safety management, and patient outcomes.

- Coordinates gap assessments and contribute to publication, congress, medical communications, and evidence-generation plans aligned with the US medical strategy.

- Supports the development and review of scientific materials, medical education content, medical information response documents, abstracts, manuscripts, and data-disclosure materials.

- Provides medical leadership for US congress planning, scientific symposia, advisory boards, and other medical activities, ensuring consistency, scientific accuracy, and compliance.

- Partners with Patient Advocacy and Grants teams to incorporate the patient and caregiver perspective and help identify appropriate independent medical e